Tag: oncology
-
Andarix Pharmaceuticals CEO to Present on Building High-Value Biotechnology Companies at Outsourcing in Clinical Trials New England Conference
FOR IMMEDIATE RELEASE October 16, 2025 Contact:Andarix Pharmaceuticals617-957-9858info@andarix.com Presentation Highlights Essential Tools and Strategies for Successful Biotech Company Formation BOSTON, MA – October 16, 2025 – Andarix Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation targeted radiotherapeutics for oncology, announced today that Chief Executive Officer Chris Adams will present on the essential tools and strategies needed…
-
Andarix Pharmaceuticals Advances Targeted Peptide Therapy Platform for Rare Cancers
CEO to Present at Major Industry Summit as Company Gains Momentum in Personalized Cancer Treatment BOSTON – July 23, 2025 – Andarix Pharmaceuticals, a clinical-stage biotechnology company pioneering targeted peptide therapies for rare cancers, today announced that CEO Chris Adams will present at the 3rd Targeted Radiopharmaceuticals Supply Chain & Manufacturing Summit in Boston on July 23-24, 2025.…
-
Andarix Pharmaceuticals CEO to Present on Targeted Radiometal Therapeutics for Lung Cancer at International Symposium on Bioorganometallic Chemistry 2025
Presentation underscores Andarix’s leadership in advancing radiometal-based cancer therapeutics and highlights partnering and investment opportunities in a rapidly growing field. FOR IMMEDIATE RELEASE August 25, 2025 Contact: Andarix Pharmaceuticals 617-957-9858 info@andarix.com Boston, MA – August 25, 2025 – Andarix Pharmaceuticals, a clinical‑stage biopharmaceutical company developing next‑generation targeted radiotherapeutics for oncology, today announced that Chief Executive Officer Chris…
-
Pioneering Targeted Therapies: Andarix Presents New Data on Radiopharmaceutical Innovations for Lung and Pancreatic Cancer
FOR IMMEDIATE RELEASE July 29, 2025 Contact: Andarix Pharmaceuticals 617-957-9858 info@andarix.com Driving New Partnerships and Investment Opportunities in Precision Oncology Radiopharmaceuticals Boston — At the 4th Targeted Radiopharmaceuticals Summit US, Andarix Pharmaceuticals is showcasing its pioneering targeted radiopharmaceutical technology for treating lung and pancreatic cancer. Company leadership is presenting recent data demonstrating how Andarix’s proprietary…
-
Andarix Pharmaceuticals CEO to Highlight Advances in Cancer Clinical Trials at Industry Conference
July 8, 2025 Contact:Andarix Pharmaceuticals617-957-9858info@andarix.com Targeted Peptide Therapy and Pioneering Cancer Clinical Trials Featured at Upcoming Event Boston, MA — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapies for rare cancers, announced today that CEO Chris Adams will deliver a keynote presentation at the Clinical Trials in Oncology Conference, taking…
-
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The abstract is entitled “Targeted Clinical Study…
-
Andarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference
ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present strategies for broad-based or basket clinical trials in lung cancer. The presentation will take place at the CBI Basket and Umbrella Trials for Oncology Conference in Philadelphia, Pennsylvania on Oct 17-18, 2018.
-
Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer
Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer has been selected to present a poster at the 6th JCA-AACR Special Joint Conference on lung cancer from July 10-12 in Kyoto, Japan.
-
Andarix Pharmaceuticals to Present at the Metals to Medicine Gordon Research Conference
Andarix Pharmaceuticals, a clinical stage company aimed at developing a targeted peptide therapies for hard to treat cancers, announced today that it will present a poster at the Metals in Medicine Gordon Research Conference .The conference will take place June 25-29 in Andover, NH.
-
Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit
Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge , MA June 19-20.